利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.024 秒)

    MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION
    1.
    发明申请
    MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION 审中-公开
    促进创伤契约的药物和方法

    公开(公告)号：US20100144690A1

    公开(公告)日：2010-06-10

    申请号：US12520496

    申请日：2007-12-23

    申请人： Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    发明人： Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

    IPC分类号： A61K31/57 ,  A61K31/575 ,  A61P17/02

    CPC分类号： A61K31/57 ,  A61K31/575 ,  A61K31/58

    摘要： Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm2 of a wound or fibrotic disorder, over a 24 hour period in order to inhibit scarring.

    摘要翻译： 提供FXR活性的拮抗剂，用作预防，减少或抑制瘢痕形成的药物。 该用途可以优选地是防止，减少或抑制伤口愈合时形成的瘢痕形成。 本发明还提供相应的治疗方法。 优选的FXR活性拮抗剂包括苦瓜酮（Z）; 格鲁斯酮（E）; 一个标准 80-574; 和5α-胆汁醇。 在有利的实施方案中，为了抑制瘢痕形成，可以在24小时内每线性cm伤口或cm2的伤口或纤维化病症提供高达32μM的FXR活性拮抗剂。

    MEDICAMENTS
    2.
    发明申请
    MEDICAMENTS 审中-公开
    药物

    公开(公告)号：US20100137201A1

    公开(公告)日：2010-06-03

    申请号：US12306501

    申请日：2007-06-29

    申请人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

    发明人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

    IPC分类号： A61K38/17 ,  C07K14/435

    CPC分类号： A61K38/1709

    摘要： There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.

    摘要翻译： 提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防，减少或抑制瘢痕形成的药物中的用途。 还提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防和/或治疗纤维化病症的药物中的用途。 另外的方面涉及可以预防，减少或抑制瘢痕形成的方法，以及可以通过哪些可以预防和/或治疗纤维化疾病。 还提供了可用于本发明的药物或方法中的治疗有效量的WNT5A或其片段或衍生物。

    USE OF WNT3A FOR ACCELERATION OF WOUND HEALING
    3.
    发明申请
    USE OF WNT3A FOR ACCELERATION OF WOUND HEALING 审中-公开
    使用WNT3A加速治疗

    公开(公告)号：US20100286055A1

    公开(公告)日：2010-11-11

    申请号：US12527185

    申请日：2008-02-14

    申请人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    发明人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    IPC分类号： A61K38/17 ,  A61P17/02

    CPC分类号： A61K38/17

    摘要： Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated. The medicaments and methods of the invention may be of particular use in accelerating the healing of skin wounds.

    摘要翻译： 提供用作加速伤口愈合的药物的WNT3A或其治疗有效的片段或衍生物。 还提供了加速伤口愈合的方法，该方法包括向受伤愈合加速的部位提供治疗有效量的WNT3A或其治疗有效的片段或衍生物。 本发明的药物和方法可以特别用于加速皮肤伤口的愈合。

    SECRETED FRIZZLED RELATED PROTEIN 3 FOR USE IN THE INHIBITION OF SCARRING
    4.
    发明申请
    SECRETED FRIZZLED RELATED PROTEIN 3 FOR USE IN THE INHIBITION OF SCARRING 审中-公开
    分泌的相关蛋白3用于抑制瘢痕形成

    公开(公告)号：US20100261659A1

    公开(公告)日：2010-10-14

    申请号：US12596332

    申请日：2008-04-17

    申请人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    发明人： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

    IPC分类号： A61K38/17 ,  A61P17/02

    CPC分类号： A61K38/177

    摘要： Provided is secreted Frizzled Related Protein 3 (sFRP3), or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. The scarring may be associated with the healing of a wound, or with a fibrotic disorder. The scarring may be associated with surgical wounds. The scarring may be scarring of the skin. The medicament may be a topical medicament, and may be suitable for local injection. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of sFRP3, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition.

    摘要翻译： 提供分泌的卷曲相关蛋白3（sFRP3）或其治疗有效的片段或衍生物，用作预防，减少或抑制瘢痕形成的药物。 瘢痕形成可能与伤口愈合或纤维化疾病有关。 瘢痕形成可能与外科伤口有关。 瘢痕可能是皮肤疤痕。 药物可以是局部药物，并且可以适用于局部注射。 还提供了预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，减少或抑制的患者施用治疗有效量的sFRP3或其治疗有效的片段或衍生物。

    Method of hatching avian eggs
    6.
    发明授权
    Method of hatching avian eggs 失效
    孵化禽蛋的方法

    公开(公告)号：US5575237A

    公开(公告)日：1996-11-19

    申请号：US481428

    申请日：1995-08-23

    申请人： Mark W. J. Ferguson

    发明人： Mark W. J. Ferguson

    IPC分类号： A01K41/00 ,  A01K67/02

    CPC分类号： A01K41/00 ,  A01K67/02

    摘要： A method of hatching eggs of avian species, especially chickens, which comprises carrying out at least one cycle of steps (a) and (c) as follows: (a) incubating the eggs in a first, baseline ambient environment which is normal for hatchery incubation of the eggs of the avian species in the prevailing climatic conditions and then during a sex-sensitive time window of embryonic development, (b) altering the ambient environment to shifted conditions for a period of time effective to bias the normal phenotypic sex ratio of the embryos, without significant adverse effect on the average mortality rate, and (c) thereafter restoring the incubation conditions to or towards normal and allowing the eggs to hatch. Preferably the ambient environment comprises a temperature of 37.5.degree.-38.degree. C. and the shifted conditions comprise reduced temperature, especially a temperature maintained at about 22.degree. C. for a period of from 18 to 42 hours. The method may be used to produce birds which are chromosomally male (ZZ) but phenotypically female or chromosomally female (ZW) but phenotypically male.

    摘要翻译： PCT No.PCT / GB93 / 02565 Sec。 371日期1995年8月23日 102（e）日期1995年8月23日PCT 1993年12月16日PCT公布。 公开号WO94 / 13132 日期1994年6月23日一种用于孵化禽类，特别是鸡的鸡蛋的方法，其包括如下步骤（a）和（c）进行至少一个循环：（a）在第一基线周围环境中孵育卵 在当前气候条件下，然后在性别敏感的胚胎发育时期窗口孵化孵化禽类物种的孵化场是正常的，（b）将环境环境改变为转移条件一段有效的时间以偏向于 胚胎的正常表型性别比例，对平均死亡率没有显着的不利影响，（c）此后将培养条件恢复到正常水平或使之正常孵化，并允许卵孵化。 优选地，周围环境包括37.5℃-38℃的温度，并且转移的条件包括降低的温度，特别是在约22℃下保持18至42小时的温度。 该方法可用于产生染色体雄性（ZZ）但表型为雌性或染色体雌性（ZW）但表型雄性的鸟。

    Connective tissue softening
    7.
    发明授权
    Connective tissue softening 失效
    结缔组织软化

    公开(公告)号：US06455569B1

    公开(公告)日：2002-09-24

    申请号：US09913713

    申请日：2001-08-17

    申请人： Mark W. J. Ferguson

    发明人： Mark W. J. Ferguson

    IPC分类号： A61K31535

    CPC分类号： A61K31/404 ,  A61K38/55

    摘要： The use of Matrix Metalloproteinase Inhibitors in the prevention or treatment of connective tissue softening and also for the maintenance of sutures in such connective tissues. The connective tissue may be a tendon, ligament or cartilage.

    摘要翻译： 使用基质金属蛋白酶抑制剂预防或治疗结缔组织软化，以及维持这种结缔组织中的缝合线。 结缔组织可以是腱，韧带或软骨。